UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer

Cancer, 2011-03, Vol.117 (6), p.1262-1271

2011

Volltextzugriff (PDF)

Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive‐stage small cell lung cancer: A retrospective analysis

Cancer, 2024-01, Vol.130 (1), p.18-30

2024

Volltextzugriff (PDF)

Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study

Journal of thoracic disease, 2022-07, Vol.14 (7), p.2645-2651

2022

Volltextzugriff (PDF)

Extensive‐stage small‐cell lung cancer: Current management and future directions

International journal of cancer, 2023-06, Vol.152 (11), p.2243-2256

2023

Volltextzugriff (PDF)

Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients

Thoracic cancer, 2021-07, Vol.12 (13), p.1943-1951

2021

Volltextzugriff (PDF)

Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer

Cancer medicine (Malden, MA), 2023-09, Vol.12 (17), p.17924-17933

2023

Volltextzugriff (PDF)

Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis

Cancer, 2011-12, Vol.117 (23), p.5423-5431

2011

Volltextzugriff (PDF)

Investigation of the efficacy and feasibility of combined therapy of PD‐L1 ‐enhanced exogenous peripatetic adoptive natural killer ( NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer

Thoracic cancer, 2023-10, Vol.14 (28), p.2877-2885

2023

Volltextzugriff (PDF)

Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer (ES‐SCLC): Study protocol

Thoracic cancer, 2024-04, Vol.15 (11), p.938-943

2024

Volltextzugriff (PDF)

Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study

Thoracic cancer, 2023-05, Vol.14 (15), p.1327-1338

2023

Volltextzugriff (PDF)

Association of antibiotic exposure with survival in patients with extensive‐stage small cell lung cancer receiving immune checkpoint inhibitor therapy

Thoracic cancer, 2024-01, Vol.15 (2), p.152-162

2024

Volltextzugriff (PDF)

Prognostic implications of neutrophil‐to‐lymphocyte ratio in patients with extensive‐stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real‐world study

Thoracic cancer, 2024-03, Vol.15 (7), p.559-569

2024

Volltextzugriff (PDF)

Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices

Cancer medicine (Malden, MA), 2023-04, Vol.12 (8), p.10020-10030

2023

Volltextzugriff (PDF)

Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis

Cancer medicine (Malden, MA), 2023-05, Vol.12 (9), p.10230-10242

2023

Volltextzugriff (PDF)

Extensive‐stage small cell lung cancer: Is prophylactic cranial irradiation necessary in the era of immunotherapy with MRI surveillance?

Precision radiation oncology, 2023-06, Vol.7 (2), p.111-117

2023

Volltextzugriff (PDF)

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period

Thoracic cancer, 2022-02, Vol.13 (4), p.539-548

2022

Volltextzugriff (PDF)

Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature

Respirology case reports, 2021-05, Vol.9 (5), p.e00741-n/a

2021

Volltextzugriff (PDF)

Cisplatin combined with irinotecan or etoposide for untreated extensive‐stage small cell lung cancer: A multicenter randomized controlled clinical trial

Thoracic cancer, 2015-11, Vol.6 (6), p.785-791

2015

Volltextzugriff (PDF)

Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting

Cancer treatment and research communications, 2024-01, Vol.39, p.100803-100803, Article 100803

Badin, Firas

2024

Volltextzugriff (PDF)

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.1073-1085

2024

Volltextzugriff (PDF)

Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials

Internal medicine journal, 2012-12, Vol.42 (12), p.1297-1309

2012

Volltextzugriff (PDF)

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy‐naive patients with extensive‐disease small cell lung cancer

Cancer, 2010-01, Vol.116 (1), p.132-136

2010

Volltextzugriff (PDF)

Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain

Acta oncologica, 2022-02, Vol.61 (2), p.185-192

2022

Volltextzugriff (PDF)

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Annals of oncology, 2020-02, Vol.31 (2), p.310-317

2020

Volltextzugriff (PDF)

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

Journal of thoracic oncology, 2021-08, Vol.16 (8), p.1403-1414

2021

Volltextzugriff (PDF)

1 – 25 von 302

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(263)
Mit Volltextzugriff
(267)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(243)
Life Sciences & Biomedicine
(236)
Oncology
(175)
Humans
(151)
Chemotherapy
(106)
Lung Neoplasms - Drug Therapy
(87)
Male
(87)
Female
(85)
Middle Aged
(84)
Aged
(76)
Lung Cancer
(76)
Small Cell Lung Carcinoma - Drug Therapy
(71)
Immunotherapy
(70)
Extensive Stage
(66)
Respiratory System
(64)
Small Cell Lung Cancer
(64)
Lung Neoplasms - Pathology
(63)
Adult
(57)
Extensive-Stage Small-Cell Lung Cancer
(57)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(54)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer

Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive‐stage small cell lung cancer: A retrospective analysis

Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study

Extensive‐stage small‐cell lung cancer: Current management and future directions

Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients

Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer

Thoracic radiation therapy improves the overall survival of patients with extensive‐stage small cell lung cancer with distant metastasis

Investigation of the efficacy and feasibility of combined therapy of PD‐L1 ‐enhanced exogenous peripatetic adoptive natural killer ( NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer

Phase III, multicenter, randomized trial of 45 Gy versus 30 Gy thoracic radiation for extensive‐stage small cell lung cancer (ES‐SCLC): Study protocol

Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study

Association of antibiotic exposure with survival in patients with extensive‐stage small cell lung cancer receiving immune checkpoint inhibitor therapy

Prognostic implications of neutrophil‐to‐lymphocyte ratio in patients with extensive‐stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real‐world study

Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices

Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis

Extensive‐stage small cell lung cancer: Is prophylactic cranial irradiation necessary in the era of immunotherapy with MRI surveillance?

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period

Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature

Cisplatin combined with irinotecan or etoposide for untreated extensive‐stage small cell lung cancer: A multicenter randomized controlled clinical trial

Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy‐naive patients with extensive‐disease small cell lung cancer

Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

Suchergebnisse filtern